{
    "id": 2889,
    "fullName": "KDM5A over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "KDM5A over exp indicates an over expression of the Kdm5a protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5927,
        "geneSymbol": "KDM5A",
        "terms": [
            "KDM5A",
            "RBBP-2",
            "RBBP2",
            "RBP2"
        ]
    },
    "variant": "over exp",
    "createDate": "01/06/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7393,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with KDM5A over expression treated with Zelboraf (vemurafenib) demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401).",
            "molecularProfile": {
                "id": 2711,
                "profileName": "KDM5A over exp"
            },
            "therapy": {
                "id": 4486,
                "therapyName": "CPI-455 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6341,
                    "pubMedId": 27214401,
                    "title": "An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with KDM5A over expression treated with AZ628 demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401).",
            "molecularProfile": {
                "id": 2711,
                "profileName": "KDM5A over exp"
            },
            "therapy": {
                "id": 4487,
                "therapyName": "AZ628 + CPI-455",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6341,
                    "pubMedId": 27214401,
                    "title": "An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7392,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma cell line with KDM5A over expression treated with Tarceva (erlotinib) demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401).",
            "molecularProfile": {
                "id": 2711,
                "profileName": "KDM5A over exp"
            },
            "therapy": {
                "id": 4484,
                "therapyName": "CPI-455",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6341,
                    "pubMedId": 27214401,
                    "title": "An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2711,
            "profileName": "KDM5A over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}